# An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

> **NCT02258854** · PHASE3 · TERMINATED · sponsor: **XOMA (US) LLC** · enrollment: 69 (actual)

## Conditions studied

- Uveitis

## Interventions

- **DRUG:** Dose 2 gevokizumab

## Key facts

- **NCT ID:** NCT02258854
- **Lead sponsor:** XOMA (US) LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2015-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258854, "An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02258854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*